Annotation of Pharmaceuticals and Medical Devices Agency, Japan (PMDA) label information
for crizotinib
and ALK
Summary
Crizotinib is indicated for the treatment of patients with non-small cell lung cancer. The PMDA package insert for crizotinib states positive confirmation of the ALK fusion gene is necessary prior to treatment.
Annotation
Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.
Excerpts from the package insert for crizotinib:
Confirmation of positive status for ALK fusion gene is necessary prior to therapy.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the crizotinib package insert (in Japanese).
*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.